Rheumatoid Arthritis Recruiting Phase 3 Trials for Methotrexate (DB00563)

Also known as: RA / Rheumatic Arthritis / Arthritis, Rheumatoid / Arthritis,Rheumatoid / Rheumatoid Arthritis (RA) / Rheumatoid Arthritis(RA) / Arthritis, Rheumatoid (RA) / Systemic rheumatoid arthritis / Arthritis rheumatoid / Rheumatoid arthritis, unspecified / R arthritis / Rh arthritis / Atrophic arthritis

IndicationStatusPhase
DBCOND0027961 (Rheumatoid Arthritis)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02722694A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to MethotrexateTreatment
NCT03980483Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexateTreatment
NCT02647762CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid ArthritisTreatment
NCT03155347An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) TherapyTreatment
NCT03414502Treatment of Rheumatoid Arthritis With Methotrexate: Predictors of ResponseTreatment
NCT02760407Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active DiseaseTreatment
NCT02760433Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Have Active DiseaseTreatment
NCT03120949Evaluation of the Long Term Safety, Tolerability and Efficacy of Two Dosing Regimens of Olokizumab (OKZ), in Subjects With Rheumatoid Arthritis (RA) Who Previously Completed 24 Weeks of Blinded Treatment in One of the Core Studies - CREDO 1, 2 or 3.Treatment
NCT03478111CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid ArthritisTreatment
NCT02837146Ultrasound as Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Very Early Rheumatoid ArthritisTreatment